Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Irinotecan, and Radiation Followed by Docetaxel in Stage III NSCLC
NCT00449020Phase 2Completed
- Sponsor
- University of Miami
- Start
- Jan 2004
- Primary completion
- May 2007
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of carboplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, docetaxel in non-small cell lung cancer (NSCLC), sponsored by University of Miami. Started Jan 2004; status: completed.
02
Drugs
carboplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00449020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00449020.